FDA Advisory Committee Recommends that Teplizumab Receives Approval
An FDA Advisory Committee weighed the evidence, and the results were positive: They recommended that the FDA approve teplizumab for at-risk individuals.
Did You Know Our Website Is Accessible for People with Disabilities?
JDRF’s website uses accessiBe technology to improve accessibility and usability for people with physical and psychiatric disabilities.
Advancing Cures with Type 1 Diabetes Clinical Trials
May 20 is Clinical Trials Day, a day to raise awareness of clinical research and the people around the world who take part in trials.
Breakthrough T1D Advocates Have Been Hard at Work
Through these meetings, advocates give a voice to those impacted by T1D.
At Any Age, Breakthrough T1D is There
Interested in joining a virtual meet-up? In need of advice from someone who’s been there? Are looking for newly diagnosed resources? Breakthrough T1D is ready to help.
A Run to Remember: Disneyland to Disney World, and Beyond
Don’s courageous effort of doing something extraordinary shows that people living with T1D truly can do anything that they put their mind to.
50+ Years with Type 1: An Interview with Dr. George King
I got the privilege of interviewing George King, M.D., whose research is on diabetes complications. Breakthrough T1D has funded him since he was early in his career.
Bigfoot Is Real—and Received FDA Clearance
The Bigfoot Unity™ Diabetes Management by Bigfoot Biomedical received FDA clearance for individuals 12 and older.
At 37, I’m Fighting to Save my Eyesight
At the age of 37, I’m fighting to save my eyesight, a complication of type 1. People are also at risk of developing kidney, heart, and nerve diseases.
National DNA Day!
Aaron Michels, M.D., discovered that methyldopa—a therapy that has been used for 50 years to treat high blood pressure—may have a role in delaying T1D.
